Kiso T, Ito S, Ohta T, Asano T, Nakazato Y
Department of Pharmacology, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Biochem Pharmacol. 1994 Jan 20;47(2):241-5.
The binding characteristics of vasoactive intestinal peptide (VIP) in the liver membranes of the dog were examined using radioligand binding assay with 125I-VIP and unlabelled peptides and results were compared with those from the rat. The binding of VIP to canine liver membranes occurred in a reversible, saturable, specific and temperature-dependent manner. Guanine nucleotides dose-dependently inhibited VIP binding. The order of potency in competition experiments with unlabelled peptide was: VIP > pituitary adenylate cyclase activating peptide (PACAP)-27 > PACAP-38 >> peptide histidine isoleucine (PHI) = secretin in the dog, and PACAP-27 > PACAP-38 > VIP > PHI > secretin in the rat. PHI and secretin were about 5000 times less potent than VIP in the dog, but secretin was about 100 times less potent than VIP in the rat. The VIP binding sites in canine liver membranes have recognition sites for VIP which differ from those in rat liver membranes. As most of VIP in the portal vein was removed during its passage through the canine liver, the binding sites of canine liver may play a role in degradation of VIP.
采用放射性配体结合分析法,利用125I-VIP和未标记的肽段检测了犬肝细胞膜中血管活性肠肽(VIP)的结合特性,并将结果与大鼠的结果进行了比较。VIP与犬肝细胞膜的结合呈现可逆、饱和、特异性和温度依赖性。鸟嘌呤核苷酸对VIP结合具有剂量依赖性抑制作用。在与未标记肽段的竞争实验中,犬体内的效力顺序为:VIP>垂体腺苷酸环化酶激活肽(PACAP)-27>PACAP-38>>肽组氨酸异亮氨酸(PHI)=促胰液素,而大鼠体内的顺序为:PACAP-27>PACAP-38>VIP>PHI>促胰液素。在犬体内,PHI和促胰液素的效力比VIP低约5000倍,但在大鼠体内,促胰液素的效力比VIP低约100倍。犬肝细胞膜中的VIP结合位点具有与大鼠肝细胞膜不同的VIP识别位点。由于门静脉中的大部分VIP在通过犬肝时被清除,犬肝的结合位点可能在VIP的降解中起作用。